Furuta S, Nakagomi D, Kobayashi Y, et al. - Via performing this randomized clinical trial, researchers sought to compare efficacy and adverse events linked with a reduced-dose glucocorticoid plus rituximab regimen vs the standard high-dose glucocorticoid plus rituximab regimen in remission induction of ANCA-associated vasculitis. A total of 140 patients with newly diagnosed ANCA-associated vasculitis were included. In the reduced-dose glucocorticoid plus rituximab group, there were 71.0% patients with disease remission at 6 months relative to 69.2% in the high-dose glucocorticoid plus rituximab group, a difference that met the prespecified noninferiority margin of −20 percentage points. These findings suggest noninferiority of reduced-dose glucocorticoid plus rituximab regimen to a high-dose glucocorticoid plus rituximab regimen with regard to induction of disease remission.